THE ARISING · EDITED READER EDITION
The Arising · November 18 Edited Reader Edition
Listen to this day’s podcast →
This edited reader edition includes 31 reviewed articles from November 18, 2026. It is not the complete original issue. It includes 31 of the original 32 stories; 1 is not included here.
Longevity & Healthspan
ACOG Updates Hormonal and Nonhormonal Options for Menopause Symptoms
The guideline separates the treatment of hot flashes and related sleep disruption from the treatment of depression.
Hot flashes, night sweats, broken sleep and low mood can overlap around menopause. A new American College of Obstetricians and Gynecologists guideline helps clinicians and patients sort out which symptoms to treat first, and which options fit their risks and preferences. The guideline covers symptoms related to spontaneous menopause or menopause induced at age 40 or older.
This is a clinical practice guideline, not a new treatment trial. ACOG's writing team reviewed the evidence and graded the strength and certainty of its recommendations. Where there was too little evidence to make a formal recommendation, the guideline offered practical advice separately.
For bothersome hot flashes and sleep disruption linked to them, hormone therapy is one option. When a patient and clinician select it and no contraindications are present, ACOG recommends beginning before age 60 or within 10 years of the start of natural menopause. That timing is not a reason to start therapy on its own. Decisions should also consider symptoms, medical history, baseline risk of cardiovascular disease, breast cancer and blood clots, and the patient's goals. Decisions about when to stop are individualized too.
The advice is different when depression is the main concern. ACOG found insufficient evidence to recommend for or against systemic hormone therapy for menopause-related depressive symptoms. When depression predominates or a patient meets criteria for major depression, ACOG advises treating it according to depression-management guidelines.
Nonhormonal choices for hot flashes include drugs that act on neurokinin receptors, such as fezolinetant and elinzanetant, and some antidepressants. Nonhormonal does not mean risk-free: fezolinetant carries an FDA boxed warning for rare but serious liver injury and requires liver testing before and during treatment. Recommendations for nondrug options, including cognitive behavioral therapy, exercise and clinical hypnosis, differ by symptom and by how strong the evidence is. ACOG did not find convincing evidence to recommend phytoestrogen or herbal supplements for these symptoms.
The practical change is a more specific clinical conversation: name which symptom is disrupting daily life, weigh the choices and agree on how to judge whether treatment is helping. This guidance is about symptom relief, not prescribing hormones to prevent chronic disease. ACOG is developing separate guidance for genitourinary symptoms of menopause.
Open this article on its own → Explore the related Living Magazine →
Longevity & Healthspan
An Eight-Hour Eating Window Did Not Add a Clear Liver-Fat Benefit
In a 12-week randomized trial, none of three eating schedules clearly outperformed a Mediterranean-style lifestyle education program on MRI-measured liver fat.
Eating in an eight-hour window lowered liver fat within each of three fasting groups in a Spanish trial. But the more useful comparison is with the group that received the same lifestyle education without shortening its eating window. That comparison did not show a statistically significant added liver-fat benefit.
The study assigned 197 adults with overweight or obesity to an early, late or self-selected eight-hour eating window, or to a usual-care group that kept its habitual window of at least 12 hours. All four groups attended sessions covering a Mediterranean-style diet, physical activity and meal planning. Participants were not assigned a calorie target.
After 12 weeks, the differences in MRI-measured liver fat relative to usual care were −0.4 percentage points for the early window, −1.5 for the late window and −0.7 for the self-selected window. None was statistically significant. The fasting schedules did not clearly differ from one another, either. The researchers also found no clear between-group differences in other liver measures or in the gut microbiota, although the study was not powered for secondary outcomes.
The fasting groups did see a difference on the scale: 41% to 44% lost at least 5% of their body weight, compared with 16% in usual care. Participants who reached that weight-loss threshold and those who started with metabolic dysfunction-associated steatotic liver disease each saw greater liver-fat reductions. Those findings are associations within the trial, not proof that weight loss alone caused the changes.
The result does not mean timing never matters, or that fasting offers no benefit. This secondary analysis was short and tested a specific question: whether adding an eight-hour window to the same lifestyle education improved liver-fat outcomes. It found no clear edge for any window. That makes the feasibility of a plan and its measured effects more useful questions than picking the supposedly best time to eat.
Open this article on its own → Explore the related Living Magazine →
Longevity & Healthspan
Midlife Fitness Was Linked to Less Colorectal and Lung Cancer in Men
A cohort study also found lower mortality after several cancer diagnoses among fitter men, but it cannot show that raising fitness changed cancer outcomes.
Men with higher aerobic fitness in midlife were less likely to be diagnosed with colorectal or lung cancer later in life. Among men who developed colorectal, lung or prostate cancer, those who started out fitter were also less likely to die from any cause during follow-up.
The researchers linked treadmill test data from the Cooper Center Longitudinal Study to Medicare claims. The cohort included 28,612 men and 4,998 diagnoses across the three cancer sites. The treadmill results were expressed in metabolic equivalents, or METs. A MET is a unit of energy use relative to resting.
Each one-MET higher level of measured fitness was associated with a 9% lower hazard of colorectal cancer and a 19% lower hazard of lung cancer after statistical adjustment. The corresponding hazard ratios were 0.91 (95% confidence interval, 0.87 to 0.96) and 0.81 (0.77 to 0.85). The researchers did not find an association with prostate cancer incidence.
After diagnosis, there were 1,549 deaths over an average of 7.1 years of follow-up. Across the three cancers, men in the high-fitness group had an estimated 33% to 41% lower relative risk of dying from any cause than those in the low-fitness group. That included generally lower mortality from cardiovascular disease and other causes. The survival result does not mean the cancers themselves responded better to treatment.
Fitness was measured, not assigned. Even with adjustments, smoking, other health habits, underlying illness and factors linked to attending the clinic could help explain the differences. The study was also conducted in men, so it cannot tell us whether the same estimates apply to women.
The useful distinction is between a measure that predicts risk and an intervention that changes it. This work strengthens the case for studying fitness in cancer prevention and survivorship. It does not quantify how much a new exercise program would lower someone's cancer risk or change their outcome after diagnosis.
Open this article on its own → Explore the related Living Magazine →
Longevity & Healthspan
Eight Pooled Trials Found No Clear Change in DNA Methylation Clocks
The finding is about scores on research biomarkers, not whether healthy habits improve health or whether aging itself slowed.
Exercise and dietary changes can improve health without moving the number on an epigenetic age test. That distinction matters in a review of randomized trials that found no clear change in these scores after diet, exercise, calorie restriction or programs combining several habits.
DNA methylation clocks use patterns of chemical marks on DNA to produce a score. Some are trained to estimate chronological age. Others are built to reflect health or mortality risk, or to estimate the pace of aging. Those are different outputs, so the reviewers studied them separately.
The review included nine randomized trials in populations with a mean age of at least 45. Eight trials, with 1,675 participants, contributed to the pooled estimates. The standardized mean difference was −0.04 for chronological-age clocks (95% confidence interval, −0.31 to 0.24), −0.17 for clocks linked to health and mortality (−0.42 to 0.09), and −0.01 for DunedinPACE, the pace-of-aging measure (−0.17 to 0.15). Every interval crossed zero. The two largest trials had a pooled estimate close to zero, and smaller trials produced the more favorable estimates.
The authors rated the certainty of the evidence as low to very low. The analysis does not rule out a small effect, particularly on the health- and mortality-linked clocks. Nor did it test whether a change in a clock score would translate into more years of healthy life.
For readers, the distinction is worth keeping: a lower clock score is not itself a reason to declare a lifestyle plan successful, and an unchanged score is not evidence that a healthful habit failed. The next useful studies would choose one primary clock before the trial starts and test whether changes in that measure track meaningful health outcomes.
Open this article on its own → Explore the related Living Magazine →
Longevity & Healthspan
Harder Supervised Exercise Improved Chair Stands and Walking More in Adults 60 and Older
In a six-month randomized trial, the clearest differences were in physical tasks. Differences in estimated muscle mass and flexibility were much smaller.
After 24 weeks of supervised exercise, adults in a high-intensity group completed an average of 5.5 more chair stands in 30 seconds than at baseline. Those in the low-intensity group gained 1.9. The moderate-intensity group fell in between, at 3.6 more repetitions.
The trial enrolled 120 community-dwelling adults aged 60 or older and randomly assigned them to three levels of effort. All followed a supervised program that combined types of exercise, with three sessions a week. The main outcome was the chair-stand test, a measure of lower-body function relevant to getting up from a seat.
The gains in walking distance followed the same pattern. In six minutes, the higher-intensity group covered 88.1 meters more than at baseline, compared with 58.0 in the moderate-intensity group and 30.8 in the lower-intensity group. The groups also improved on a timed test of standing, walking a short distance and sitting again, with the largest change at the higher intensity.
It would be a mistake to apply those gains to every outcome. Differences in flexibility were smaller. Estimated skeletal muscle mass increased by 0.7 kilograms in the higher-intensity group and 0.2 in the lower-intensity group, with a small standardized difference. Body composition was estimated by bioimpedance rather than measured directly.
Of the 120 participants, 111 completed follow-up. No serious adverse events were reported, but the trial was small, took place at one site and involved supervised sessions. There was no nonexercise group. It compared ways of training, not starting exercise versus doing nothing, and did not establish whether the gains translate into fewer falls, lasting independence or the same safety without supervision.
The useful takeaway is that effort level made a difference to some everyday tasks in this setting. The next question is how to individualize that effort for people with different health and mobility limits, and whether the gains hold up over longer follow-up.
Open this article on its own → Explore the related Living Magazine →
Longevity & Healthspan
Higher Protein During Calorie Restriction Modestly Preserved Fat-Free Mass
The average difference was about a quarter of a kilogram, and fat-free mass is not the same as muscle mass or strength.
Adults who ate more protein while restricting calories retained modestly more fat-free mass and lost slightly more fat than adults in the comparison groups. The finding comes from a review of 33 randomized studies involving 2,135 people with overweight or obesity.
The higher-protein groups retained, on average, 0.26 kilograms more fat-free mass (95% confidence interval, 0.04 to 0.48 kilograms). They also lost 0.69 kilograms more fat on average (0.42 to 0.95 kilograms). Fat-free mass includes muscle but also includes water, organs and other tissues. A change in this measure does not establish the same change in muscle or show that people became stronger.
The authors also asked whether exercise changed the result. The subgroup comparison of studies with and without exercise did not show a clear difference in fat-free mass. An exploratory analysis found a larger difference, about 0.49 kilograms (0.14 to 0.83), when higher protein was paired with exercise. That analysis is a reason to test the combination directly, not evidence that it works better for a particular age group.
The overall effect on fat-free mass was smaller than some earlier reviews had reported, and the trial results varied. The studies compared dietary approaches during calorie restriction, not during treatment with GLP-1 medicines. They do not establish a universal protein target or show what happens to strength and function during medication-assisted weight loss.
For people following a weight-loss program, the study makes a useful distinction between losing weight and what is being lost. The next useful trials would measure not just body composition but strength and mobility, and test whether a nutrition-and-exercise plan changes those outcomes during treatment.
Original systematic review in The American Journal of Clinical Nutrition
Open this article on its own → Explore the related Living Magazine →
Longevity & Healthspan
Shorter Activity and Temperature Rhythms Weakened in Aging Mice
The 24-hour cycle remained detectable, but shorter rhythms grew weaker and less coordinated.
In older mice, physical activity and core body temperature still followed a daily rhythm. The same recordings showed something the daily cycle could miss: weaker rhythms repeating every two to six hours and less coordination between activity and temperature.
Researchers at the University of Tsukuba studied male mice and examined a brain region called the suprachiasmatic nucleus, which helps coordinate the body's daily rhythms. Older mice showed changes in the activity of genes linked to immune signaling and in cells that support neurons, even though several core clock genes still rose and fell over the day.
The physiological recordings and brain analyses came from separate groups of mice. That means the researchers could not show that the brain changes caused the rhythm changes, or even that both occurred in the same individual animal. They also did not study people or consumer wearables.
The next question is whether these shorter rhythms weaken in older people and, if they do, whether measuring them reveals anything that changes care.
A daily cycle and the shorter rhythms within it answer different questions. The first describes whether activity and temperature vary with the time of day. The second can show whether those changes stay coordinated over shorter stretches. In this study, a daily pattern that was still detectable did not mean that the shorter patterns had been preserved. The result is a reason to distinguish the two measures, not to treat the shorter rhythms as a new marker of human aging.
Open this article on its own → Explore the related Living Magazine →
Longevity & Healthspan
A Protein Tag Helped Explain Blood Vessel Dysfunction in Mice
Experiments in cells and mice point to a pathway in the blood vessel lining, not a treatment.
The inner lining of a blood vessel helps it widen when tissues need more blood. In a study published in eLife, researchers investigated how high blood fats can interfere with that function. They found that attaching a small molecular tag called SUMO2 to a protein called p66Shc promoted oxidative stress in endothelial cells, the cells that line blood vessels.
In mice with elevated blood lipids, the vessel lining kept working better when the protein could not receive that tag. The finding helps explain one way that high blood lipids can impair vessel function in these experiments. It does not establish that blocking the pathway prevents plaque buildup, heart attacks or strokes, or that the same intervention would work safely in people.
The next step is to find out whether the preserved function in mice translates into less disease. Nothing in this study changes how patients should manage cholesterol.
The cell experiments also helped distinguish the tag from the total amount of the protein. The researchers’ evidence suggests that how the protein is modified matters for what it does. The tag promoted changes that helped the protein move into mitochondria, where it contributed to the production of reactive oxygen species. That offers a way to connect a molecular event in a cell to a change in how the vessel lining works. It remains an explanation for the observations in those experimental systems, not a validated target for a drug.
Open this article on its own → Explore the related Living Magazine →
Longevity & Healthspan
Vagus Nerve Stimulation Made Little Difference to Sleep in a Small Trial
The change in self-reported sleep fell short of the study's threshold for a clinically meaningful improvement.
Vagus nerve stimulation is marketed as a way to improve sleep and reduce stress. In a double-blind pilot trial of 29 healthy adults, each participant used an active device and an inactive look-alike for four weeks each.
Participants rated their sleep slightly better with active stimulation than with the inactive device, but the average change was smaller than the study's threshold for a clinically meaningful improvement. The two depression scales showed no significant change, and heart rate variability did not differ across the group.
There were no serious adverse events in this small trial. Three participants reported temporary ear discomfort or tingling during active stimulation. The researchers studied healthy adults, not people with insomnia or depression. The results do not establish that the device treats either condition.
The difference between statistical and clinical significance matters here. The researchers could detect a difference on a questionnaire, but it was not large enough on average to meet the threshold they used for a meaningful change. The sleep measure was subjective: it tells us how participants rated their sleep, not whether their sleep stages or time spent asleep improved. The crossover design let participants serve as their own comparison, but the small sample still limits what can be concluded about benefit or harms. A larger study in people with sleep problems would need to show an effect big enough for patients to notice.
Open this article on its own → Explore the related Living Magazine →
Longevity & Healthspan
A Blood Marker Helped Estimate Future Risk of Cognitive Impairment
A model put five- and ten-year numbers on risk. Whether using those numbers improves care remains untested.
Alzheimer's-related changes can appear years before symptoms, but a biomarker alone does not tell someone whether or when they will develop symptoms. Researchers asked whether a blood marker called p-tau217 could help estimate that risk when combined with age, sex and APOE ε4 status.
The analysis included 2,178 adults aged 60 to 90 from two research cohorts. All were cognitively unimpaired at the start. Higher p-tau217 was associated with a higher rate of progression to cognitive impairment.
In an illustrative example based on the Mayo Clinic cohort, the modeled five-year risk of mild cognitive impairment at age 75 was 7% at a p-tau217 concentration of 0.072 pg/mL and 17% at 0.324 pg/mL, holding sex and APOE ε4 at the cohort averages. The corresponding ten-year estimates were 15% and 35%. These are model estimates for a specified example, not screening cutoffs or predictions of what will happen to any one person.
One potential use is identifying people more likely to develop impairment when recruiting for prevention trials. The study did not test whether offering the blood test to people without symptoms improves decisions or outcomes. It used one laboratory platform, and the estimates need to be tested in broader populations. The FDA-cleared Lumipulse ratio test has a different purpose: it helps evaluate people with cognitive symptoms and is not intended for screening.
Risk estimation is also different from diagnosis. The researchers modeled whether people progressed from unimpaired cognition to mild cognitive impairment or dementia over time. These estimates are not probabilities that a person currently has Alzheimer's disease.
Open this article on its own → Explore the related Living Magazine →
Longevity & Healthspan
No Clear Benefit for NAD+ Boosters in Small Heart Failure Trials
A pooled analysis found no reliable improvement in hospitalization, survival or the heart's pumping function.
A review pooled four randomized trials involving 387 adults with symptomatic heart failure. The trials tested intravenous NAD+ or oral nicotinamide riboside, which the body can use to make NAD+, against placebo. Participants were already receiving guideline-directed treatment.
Across three trials, the relative risk of heart failure hospitalization was 0.63 with the NAD+-related interventions compared with placebo (95% confidence interval 0.36 to 1.09). The estimate for all-cause mortality was even less precise: 0.51 (95% confidence interval 0.09 to 2.86) across two trials. Neither result established a benefit, and the review found no statistically significant improvement in left ventricular ejection fraction, a measure of how much blood the heart pumps out with each beat.
In two trials involving 209 patients, creatinine was on average 7.46 µmol/L higher with NAD+ (95% confidence interval 2.21 to 12.71). That is a laboratory safety signal to study, not proof of kidney injury.
These studies do not give patients a reason to add NAD+ products to standard heart failure treatment. Larger, longer trials would be needed to tell whether these interventions help or harm.
The uncertainty is important: the intervals around the results were wide enough to include both a meaningful benefit and no benefit. The review also grouped two distinct interventions, so its overall estimate is not evidence that either one works on its own. It did not test healthy adults who take NAD+ products for longevity.
Open this article on its own → Explore the related Living Magazine →
Longevity & Healthspan
Fast, Light Resistance Training Modestly Raised Hip Bone Density After Menopause
The eight-month supervised trial measured bone density, not whether women had fewer fractures.
Could the speed of a lift matter for bone as well as the weight? In the REPROOF trial, researchers randomly assigned 109 healthy postmenopausal women aged 50 to 70 to supervised fast, light resistance training; slower, heavier resistance training; or a control group. Eighty-two women completed the eight-month study.
Compared with controls, the fast, light group gained 0.008 g/cm² in total hip bone mineral density (95% confidence interval 0.001 to 0.014), a small change. The slower, heavier group did not show a significant hip difference versus controls, although it did show changes in shin-bone structure. A significant result for one group versus controls and a nonsignificant result for the other do not, by themselves, establish that the groups differed from each other.
The study did not establish whether the density change prevents fractures. It also does not show that unsupervised fast lifting is appropriate for people at high fracture risk. What it does show is that a supervised, lighter-load program can affect hip density in this setting, giving researchers a reason to test it in larger and longer trials.
That distinction matters because bone density is an intermediate measure. Whether a program helps someone avoid a fracture depends on more than the density scan, and this trial cannot settle that question. The study also cannot say whether the gain persists once supervised training ends. Attrition also matters: 27 of the 109 randomized participants did not complete the study.
Open this article on its own → Explore the related Living Magazine →
Longevity & Healthspan
A newer Moderna COVID shot was linked to fewer hospitalizations in older veterans
A VA study found an adjusted difference of about two COVID hospitalizations per 10,000 people. Hospitalization was uncommon with both vaccines.
Among 294,499 U.S. veterans aged 65 and older in a matched observational study, those who received Moderna’s mRNA-1283 vaccine had fewer COVID hospitalizations than those who received Pfizer–BioNTech’s BNT162b2 vaccine. Both shots were formulated for the LP.8.1 strain during the 2025–26 season. The researchers followed participants for up to 150 days.
The primary outcome was COVID that led to medical care, including antiviral treatment. It occurred in 86 of 55,349 people who received the Moderna shot (0.16%) and 672 of 239,150 people who received the Pfizer shot (0.28%). After adjustment, the estimated difference was 10 fewer cases per 10,000 people, equivalent to a 35.9% lower relative risk (95% credible interval, 20.4% to 49.7%).
Hospitalization was a secondary outcome. There were 11 COVID hospitalizations in the Moderna group (0.02%) and 114 in the Pfizer group (0.05%). After adjustment, the difference was 2.2 fewer hospitalizations per 10,000 people (95% credible interval, 0.2 to 3.8 fewer), or a 47.0% lower relative risk. The relative estimate was imprecise, and some alternative analyses were compatible with no difference.
The study did not assign people to vaccines at random. Even after matching and adjustment, differences between the groups could explain some of the result. Some outcomes the vaccines were not expected to affect also differed between groups. Moderna helped fund the research, and company employees took part in the study. The population was predominantly male, and the findings reflect a single respiratory-virus season.
The distinction between relative and absolute risk matters. A 47% difference sounds large, but very few people in either group were hospitalized. This comparison is useful evidence for older adults like those studied; it does not establish that one shot will outperform the other in every population or season.
Open this article on its own → Explore the related Living Magazine →
Longevity & Healthspan
A federal clinical AI roadmap puts outcomes at the center of payment
HHS wants to test whether technology-supported care improves patients’ health. The roadmap does not require doctors to use AI or grant new authority to autonomous tools.
A federal roadmap lays out how the Department of Health and Human Services wants to evaluate, monitor and pay for clinical AI. It proposes starting with lower-risk uses, monitoring results as tools are used, and allowing more autonomy only when evidence supports it. It also calls for better data sharing with patient consent and clearer accountability when systems make mistakes.
One piece is already underway. In July, the Centers for Medicare & Medicaid Services launched ACCESS, a voluntary Original Medicare pilot for technology-supported chronic care. Participating care organizations are paid to manage qualifying conditions, and full payment depends on the share of their patients who reach defined outcomes. For high blood pressure, for example, the measure can be whether patients bring their blood pressure down, rather than how often they use an app. The model requires physician oversight and is meant to complement existing care.
HHS says it expects to extend that approach to more parts of primary care and wants to work with states on additional payment tests, including in Medicaid. Those are proposals, not a new nationwide rule paying for every AI-enabled service. ACCESS itself is not limited to AI.
On safety, a separate FDA discussion paper describes a potential way to assess certain generative AI-enabled medical devices before marketing. It pairs benchmark tests with clinical confirmation. It is not a requirement that all chatbots pass a physician’s exam. An ARPA-H project, ADVOCATE, is also seeking to develop and evaluate AI that could support cardiovascular care between visits. FDA authorization is a goal of that program, not something the project announcement says it has secured.
The practical question for a health system is whether a tool can produce better results than existing care without creating new problems. That means tracking what happens after an alert, who responds when the tool gets it wrong, and whether patients are healthier. A faster answer is useful; an improvement in care is what this payment model is meant to measure.
Read the federal clinical AI roadmap
Read the ACCESS model from CMS
Open this article on its own → Explore the related Living Magazine →
Longevity & Healthspan
A mouse study finds mitochondrial stress even when energy production holds up
In a Parkinson’s-like mouse model, signs of trouble moving proteins into mitochondria accompanied more inflammation, protein clumping and problems with coordination.
Mitochondria are usually described as the parts of a cell that make energy. But they also depend on a supply chain: most of their proteins are made elsewhere in the cell and have to be moved inside. If that process is disrupted, proteins can accumulate where they don’t belong, even when the mitochondria still appear to make energy normally.
Researchers at SUNY Upstate Medical University studied that possibility in mice. They found signs of stress from misplaced proteins without detecting a reduction in overall energy-producing capacity. When they examined this stress in a mouse model of Parkinson’s-like disease, the mice had larger clumps of alpha-synuclein, more inflammation in the nervous system and worse motor coordination than mice with the Parkinson’s-like model alone.
The study separates two questions that are often treated as one: Can the mitochondria still supply energy, and can the cell keep its proteins in the right place? In this experiment, the energy measurements did not detect the additional problems seen in the mice. The researchers inferred that protein import was disrupted from the patterns they observed; they did not directly measure the rate of import in nervous tissue.
This is evidence about a possible mechanism in a mouse model. It does not establish that the same process drives Parkinson’s disease in people, or that changing mitochondrial protein import would treat it. The next question is whether the mechanism can be demonstrated directly and whether it matters in human disease.
Open this article on its own → Explore the related Living Magazine →
Longevity & Healthspan
Isomorphic Labs raises $5 billion for AI drug design
The financing will help Demis Hassabis’s company move drug candidates toward trials in people. It does not tell us whether those drugs will work.
Isomorphic Labs announced a $5 billion Series C financing on November 17. Greenoaks and Sequoia Capital co-led the round, with participation from Alphabet, Andreessen Horowitz and other investors. The London-based company announced a separate $2.1 billion Series B in May, bringing its disclosed financing from these two rounds to $7.1 billion this year.
The company plans to use the money to expand its AI drug-design platform, grow its internal and partnered pipelines, and build the infrastructure needed to move candidates into clinical studies. It reports encouraging preclinical results from its own oncology and immunology programs and from work with partners. The announcement does not contain human trial results.
There are two different kinds of progress here. A model can help researchers decide what to test next. That matters when many plausible designs would be slow and expensive to explore in the lab. But a candidate that looks promising in a model or a preclinical study can still fail in people. Clinical trials have to establish what dose patients can tolerate, whether the drug helps, and whether its benefits outweigh its harms.
The next milestone to watch is not a larger round or a better benchmark. It is a registered human study of an Isomorphic candidate, followed by results showing how the drug actually performs. This is a major investment in a platform for developing medicines across several diseases, not $5 billion earmarked for aging biology or proof that the platform extends healthy life.
Open this article on its own → Explore the related Living Magazine →
Longevity & Healthspan
A small Alzheimer’s trial tests an antibody that changes immune activity
The 40-person safety study found immune-related side effects and did not show that the treatment slows cognitive decline.
Some experimental Alzheimer’s treatments aim at amyloid or tau. IBC-Ab002 takes a different approach: it temporarily blocks PD-L1, part of a system that normally restrains immune activity. Researchers want to know whether changing that activity can help the brain, but the first human trial was designed mainly to learn about safety, not to answer whether patients get better.
The randomized, double-blind phase 1b trial enrolled 40 people with early Alzheimer’s disease across 11 sites. Thirty received the antibody and 10 received placebo. The results, published in Nature Medicine in July, showed that a measure of immune activity in the blood rose after infusion and returned near baseline before the next infusion. That is evidence that the drug affected its intended pathway, not that it changed the course of the disease.
Researchers observed no serious adverse events they attributed to treatment, and no cases of the brain swelling or bleeding seen on scans with some amyloid-targeting antibodies. But 10 of 30 people who received the drug had immune-related side effects, compared with one of 10 on placebo. One participant developed persistent low thyroid function requiring treatment. Another developed a marked liver enzyme elevation without symptoms that later resolved. Three people in the treatment group stopped the drug because of side effects. Forty participants is too few to rule out uncommon or longer-term harms.
Exploratory spinal-fluid tests suggested that some markers of nerve and synapse damage might have fallen at the highest dose. That comparison used paired samples from five people at the highest dose and six people on placebo. None of the marker differences was statistically significant. It is not evidence that patients thought more clearly, functioned better or declined more slowly.
The next meaningful result would come from a larger trial that can measure changes in memory and day-to-day function alongside harms. Until then, the findings support studying the approach further, not using it to treat Alzheimer’s disease.
Open this article on its own → Explore the related Living Magazine →
Longevity & Healthspan
A blood test can help guide a new treatment for some advanced breast cancers
The FDA approved giredestrant with everolimus for a specific form of advanced breast cancer. In the relevant trial group, the combination delayed progression; whether it extends life is not yet known.
A blood test can change the next treatment choice for some people whose breast cancer has returned or grown despite endocrine therapy. The test looks for a change in ESR1, the gene that encodes the estrogen receptor. It does that by reading fragments of tumor DNA circulating in the blood.
On November 16, the FDA approved the oral drug giredestrant (Wilserdly) in combination with everolimus for adults with estrogen receptor-positive, HER2-negative, ESR1-mutated breast cancer that is locally advanced or metastatic. The cancer must have recurred during or after endocrine treatment given after surgery, or progressed after at least one endocrine-based treatment for metastatic disease. The FDA also authorized FoundationOne Liquid CDx as a companion blood test for identifying eligible patients. This approval is not for early-stage disease or for giredestrant by itself.
The phase 3 evERA trial randomly assigned 373 people to giredestrant or an endocrine treatment chosen by their physician. Both groups received everolimus. Trial participants had previously received a CDK4/6 inhibitor plus endocrine therapy. Among the 207 participants with an ESR1 mutation, the median time before the cancer worsened or the participant died was 10.0 months with giredestrant and 5.5 months with the comparison treatment. The hazard ratio was 0.38 (95% confidence interval, 0.27 to 0.54). At the time of that analysis, there were not enough overall survival data to know whether patients lived longer.
The combination has meaningful side effects. Common reactions included mouth sores, rash, fatigue, diarrhea, muscle or joint pain, inflammation in the lungs and nausea. Giredestrant also carries warnings about slow heart rate and potential harm to a developing fetus.
What matters here is the link between the test and the next decision. The blood test does not diagnose breast cancer or predict exactly how long a treatment will work for an individual. It can identify a tumor change that helps the oncology team decide whether an approved treatment is an option.
Longevity & Healthspan
Staying engaged was linked to modestly better thinking in older adults
A review of 52 studies found a small association between cognitive performance and staying mentally, socially or physically active. It did not show that activity prevents dementia.
Older adults who reported or showed more engagement in activities tended to perform somewhat better on tests of thinking, according to a new meta-analysis. Researchers pooled 52 studies covering 60 independent samples and 52,621 healthy older adults.
The pooled correlation was 0.15 (95% confidence interval, 0.12 to 0.18). That is a small positive relationship. The association was stronger for cognitive activities and for mixes of activities than for other categories. It does not mean that a specific class, hobby or exercise routine will improve someone’s memory.
The direction of the relationship matters. Staying engaged might help people maintain some thinking skills, but people who already have better cognition may also find it easier to take up or keep doing activities. Health, education and access to activities can affect both. Pooling many studies can estimate the size of the association more precisely; it cannot establish which explanation is right.
The researchers examined 682 estimates of the relationship between activity and thinking. Those were not 682 independent groups of people: a study could report several results from the same participants. The team used a statistical method that accounts for those results being related. That makes the pooled estimate a better summary of the studies, but it does not turn a test score into a measure of someone’s future dementia risk.
The findings support asking better questions about how older adults spend their time. The next test is whether assigning people to specific activities, and following them long enough, changes outcomes they care about: memory, independence and everyday function.
Open this article on its own → Explore the related Living Magazine →
Longevity & Healthspan
FDA Cleared Updated Cleerly Software to Measure Coronary Plaque
The company drew on a more diverse registry cohort to update its AI model. That is not the same as proving that the update improves patient outcomes.
Coronary CT angiography can reveal plaque in the heart’s arteries, including plaque that does not severely narrow them. Cleerly’s software helps trained clinicians identify, characterize and quantify that buildup on scans they are already evaluating. The software does not replace a clinician’s interpretation.
The FDA issued separate 510(k) clearances for an updated Cleerly LABS and the Cleerly Plaque module on July 29, 2026. Cleerly announced the clearances on October 30 and said it planned to make the update available to customers in November.
The company says the updated plaque model draws on a CONFIRM2 registry cohort of 6,550 people from 46 countries, about half of them women. That describes the registry cohort used to inform the model, not necessarily the entire training set. Broader representation is valuable, but it does not show by itself that the update performs equally well across groups. The clearance is not a green light for population screening or evidence that using this version prevents heart attacks. The next useful test is whether the measurements improve treatment decisions and outcomes in routine care.
Plaque measurements and narrowing answer related but different questions. One describes the buildup in the artery wall; the other describes how much space remains for blood to flow. Software can help report both from an existing scan, but the clinical question is still what to do with that information. A useful evaluation would distinguish better agreement between readers from a change in preventive care, and then ask whether the change benefits patients.
FDA clearance: Cleerly LABS · FDA clearance: Cleerly Plaque · Cleerly announcement
Open this article on its own → Explore the related Living Magazine →
Longevity & Healthspan
A Study of 965 Pet Dogs Maps How Biological Systems Age Together
The Dog Aging Project analysis is a preprint, not a validated way to predict how long a dog will live.
Companion dogs share many of our environments, but they age on a shorter timetable. That makes them useful for asking how different parts of the body change together over time.
In a preliminary analysis of data from 965 Dog Aging Project participants, researchers examined the microbiome, chemical marks on DNA, small molecules in blood and immune cell profiles alongside clinical and lifestyle information. Age accounted for the strongest pattern of variation across the measures, and some aging patterns differed with breed size. The authors also identified a combined molecular signature associated with aging.
These are observational findings, not evidence that a treatment can slow aging. The study has not been peer reviewed, and the signature does not yet give an individual dog a reliable prognosis. A useful next step would be to see whether it predicts meaningful health changes in an independent group of dogs, beyond what age and breed size already tell us.
The value of combining measurements is that each tells a different part of the story. Changes in blood chemistry, for example, need not follow the same pattern as changes in immune cells. Looking across those measurements can show which changes tend to travel together. It cannot, on its own, establish which changes drive aging and which are consequences of it. That distinction matters before such a signature is used to judge whether an intervention works.
Open this article on its own → Explore the related Living Magazine →
Markets & Strategy
Alzheimer’s Pill Shows a Signal in One Prespecified Group, Not the Full Trial
AriBio reported a smaller decline with its experimental pill in a group without certain background Alzheimer’s medications. The full trial population showed no statistically significant difference.
The phase 3 POLARIS-AD trial randomized 1,535 people with early Alzheimer’s disease to AR1001 or placebo for 52 weeks. The trial measured change on a scale that combines cognition and daily function. It tested that same outcome in two prespecified populations, with a statistical rule that allowed the trial to meet its efficacy objective in either one.
In the full population, the difference versus placebo was −0.11 points and was not statistically significant. In the 604-person population not taking a cholinesterase inhibitor or memantine at baseline, AriBio reported a −0.44-point difference, or 31% less decline relative to placebo (p = .0266). That means slower worsening on the study scale, not an improvement from baseline. The company reported the findings at a conference; they do not establish benefit for the wider Alzheimer’s population or explain why the two results differed.
AriBio’s commercial partner Fosun reported diarrhea in 7.7% of patients receiving AR1001 versus 4.4% on placebo, and serious adverse events in 10.0% versus 9.8%. The drug remains investigational. The next test is a full review of the results, including whether the difference is large enough to matter in daily life and what regulators make of it.
A relative percentage gives only part of the picture. The absolute gap was less than half a point on the trial scale, and the sponsor did not show a significant difference when all participants were analyzed together. The finding raises a question for further work: does the treatment have a reproducibly different effect in people who start without those other medicines?
ClinicalTrials.gov: POLARIS-AD · AriBio topline results · Fosun disclosure
Open this article on its own → Explore the related Living Magazine →
Markets & Strategy
Senior Housing Construction Slowed Despite Strong Demand
An industry analysis points to a gap between filling buildings and earning enough to build more of them.
Annual U.S. senior housing construction starts fell from more than 30,000 units in 2021 to about 10,000 in 2025, despite four consecutive years of record absorption, according to a report by NIC MAP and Argentum. Strong demand can fill existing communities without making the next project financially viable.
The authors found that net operating income per unit rose above its pre-2020 trend in 2025, even though operating margins were still 6.6 percentage points below their pre-2020 level. Staffing costs also moved differently across segments: as a share of revenue they eased after 2022 in assisted living but continued to rise in independent living.
These are industry benchmarks, not proof that staffing costs caused the national construction slowdown. The report’s financial model does suggest why local projects can behave differently: rents and costs vary by market, and the conditions that support new assisted living are not necessarily the same as for independent living. For families and planners, the practical question is where demand is actually translating into new units.
The distinction between margins and income per unit is useful here. A property can bring in more dollars per unit and still retain a smaller share of its revenue after paying operating costs. That makes an occupancy figure or a rent figure insufficient on its own. Developers and lenders need to consider those measures alongside staffing and other recurring expenses before deciding whether a project can support new construction.
Markets & Strategy
Draft U.S. Insurance Guidance Addresses Long-Term Care Reserves
Regulators are examining the assets behind some reinsured policies. Draft guidance does not change benefits for policyholders.
Draft materials from the National Association of Insurance Commissioners say long-term care insurance is an asset-intensive business for purposes of Actuarial Guideline 55. The guideline deals with whether assets backing certain reinsured obligations are sufficient under adverse conditions. For long-term care, claims may arrive many years after a policy is sold, making the long-run strength of the assets relevant.
The Dallas fall meeting agenda also lists consideration of a proposal for a separate capital charge tied to certain reinsurance in jurisdictions that do not qualify as reciprocal. Committee materials identify risks in some arrangements that combine riskier investments with generous annuity guarantees. Those findings concern particular life insurer reinsurance arrangements; they are not a measure of weakness across the long-term care insurance market.
The development to watch is what regulators ultimately adopt and which transactions it covers. Neither the draft language nor the meeting agenda is evidence of a new requirement in force or a change to existing benefits.
There are two distinct questions in these documents. One is whether the assets behind a reinsured block can continue paying claims under difficult conditions. The other is how much capital an insurer should hold against the risk associated with certain reinsurance transactions. The draft guidance and the separate capital proposal address those questions from different angles. Neither says that every long-term care insurer is affected in the same way.
Markets & Strategy
EU Medicines Committee Backs Baxdrostat for Hard-to-Control Blood Pressure
The European Commission still has to decide whether to authorize the medicine in the EU.
The European Medicines Agency’s human medicines committee recommended on November 12 that Baxfendy (baxdrostat) be authorized for adults whose blood pressure remains insufficiently controlled despite at least two antihypertensive medicines.
Baxdrostat suppresses production of aldosterone, a hormone that helps regulate salt and water balance. The committee cited randomized, placebo-controlled studies showing reductions in systolic and diastolic blood pressure. Those results describe blood pressure control, not proof that this medicine reduces strokes or heart attacks. The agency identified elevated potassium as its most common side effect.
The recommendation is not EU marketing authorization. The November meeting record lists the European Commission decision as pending, and EMA says the detailed European prescribing information will follow if authorization is granted.
The committee’s language also matters for who might be offered the medicine. Its recommendation is for adults whose pressure remains too high despite treatment, not for all adults with a new diagnosis. Because the trials measured blood pressure, the finding answers whether the drug can bring that number down in the studied setting. It does not settle how much benefit or harm patients might experience over longer follow-up, or how the treatment compares with every other option for hard-to-control hypertension. If the Commission authorizes it, clinicians will have the final prescribing information to consult, including how the drug should be used and what precautions apply.
Open this article on its own → Explore the related Living Magazine →
Markets & Strategy
Experimental Cell Therapy Shows a Walking Signal in a Small Frailty Trial
The difference emerged at nine months. The direct dose-versus-placebo comparisons had not reached statistical significance at six months.
A phase 2b trial randomly assigned 148 ambulatory older adults with frailty to different doses of an investigational cell therapy, laromestrocel, or placebo. The main measure was how far participants could walk in six minutes.
At six months, no single dose showed a statistically significant difference from placebo, although a separate prespecified analysis found that walking performance improved more as the dose increased. By nine months, the highest-dose group had improved by 63.4 meters more than placebo (95% confidence interval, 17.1 to 109.6 meters). At that visit, the walking results for those groups were based on 15 participants receiving the highest dose and 26 receiving placebo.
Serious events were comparable across groups in this small study. Two participants died, one in a treatment group and one in the placebo group; investigators did not attribute serious events to the product. The trial found no statistically significant differences in falls, fractures or hospitalizations. The walking result warrants a larger trial, but it is not proof that the therapy prevents disability, reverses frailty or extends life.
The two analyses at six months asked different questions. The direct comparison asked whether any individual dose clearly beat placebo. The dose-response analysis looked for a pattern across groups. The later result is encouraging because walking is a practical measure of function, but a short walking test cannot substitute for evidence about maintaining independence. Larger studies need to show whether patients walk farther in daily life and whether any benefit lasts.
Open this article on its own → Explore the related Living Magazine →
Longevity & Healthspan
An Experimental Tau Drug Shows a Signal, but the Trial Missed Its Main Goal
Biogen reported a difference in an early Alzheimer's study extension. By then, the study was no longer a blinded comparison against placebo.
An Alzheimer's drug called diranersen takes a different approach from treatments that clear amyloid: it is designed to reduce the production of tau, another protein implicated in the disease. At the Clinical Trials on Alzheimer's Disease conference, Biogen reported new follow-up from its phase 2 CELIA study. The results are a reason to run a confirmatory trial, not evidence that patients should expect a benefit.
The trial enrolled 416 people with mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's dementia. For the first 76 weeks, participants and study staff did not know who received one of three drug regimens or placebo. The prespecified primary test asked whether the clinical response varied with dose at week 76. Biogen previously reported that the trial did not meet that endpoint. Some secondary measures favored the lowest-dose group, but that does not change the result of the primary test.
By week 96 the study had moved into an open-label extension. Biogen reported a 1.09-point difference on the Clinical Dementia Rating–Sum of Boxes, a clinician-rated measure of cognition and everyday function. The analysis compared people who continued their assigned lower dose with people who originally received placebo and entered the extension. By that point, the latter group had received no active doses or one active dose. Participants who continued into the extension are a selected group, and the comparison was no longer blinded. It cannot carry the same weight as a result from a blinded placebo-controlled trial.
During the controlled period, frequently reported adverse events included procedure-related pain, symptoms following lumbar puncture and episodes of confusion. The sponsor reported no new safety signals in the extension; that does not establish long-term safety.
The next test is whether a larger, blinded trial can reproduce a benefit on a prespecified measure people and caregivers care about, with an acceptable burden of harms. Diranersen remains experimental.
CELIA trial registry and primary outcome
Open this article on its own → Explore the related Living Magazine →
Longevity & Healthspan
More Rodents Were Alive at the End of Some Safety Studies. Did They Live Longer?
A look back at regulatory records found unexpected survival signals. The records cannot tell us whether the animals gained years of life.
Long-term safety studies are designed to detect harm. But records from those studies can also turn up unexpected patterns. Researchers looked back at regulatory studies in rats and mice to ask a narrow question: Were more animals in some exposed groups still alive at the end of the study than in the corresponding control groups?
Of 154 substances in qualifying studies, 27 had at least one comparison with a statistically significant increase of 10% or more in survival at the study's end. That is a signal to investigate, not evidence that 27 substances lengthen life. Survival at a fixed cutoff counts how many animals crossed a particular point in time. It cannot tell us from that number alone how long they lived after that point or how their health changed along the way.
The way the archive was searched matters too. Many substances had multiple comparison groups, and a result in one group is not the same as a consistent effect across groups. Looking for patterns after a study is over can uncover a question nobody thought to ask at the time. Answering it requires confirming the pattern in an independent study designed around that question.
This is an example of how existing data can help scientists decide which questions deserve follow-up. It is not a reason to use a pesticide to try to live longer. The work did not test people or establish a safe or effective human intervention.
Open this article on its own → Explore the related Living Magazine →
Longevity & Healthspan
A Map of the Gut's Viruses Shows What an Association Can and Cannot Tell Us
The study found thousands of links to compounds in the gut, but it could not tell which changes came first.
The gut contains viruses that infect bacteria. Researchers looking at data from 1,069 participants in the TwinsUK cohort built a catalogue of 116,740 distinct genetic groups of these viruses. An individual carried about 3,370 of the groups on average, most at low abundance. This was a catalogue built from the genetic data, not a count of the number of viral particles in each person.
The catalogue let the researchers ask which viruses appeared alongside particular bacteria or compounds in the gut. They found 6,572 viral groups associated with short-chain fatty acids or secondary bile acids, compounds that gut microbes produce or modify. These links describe what tended to appear together across participants. They do not establish whether the viruses changed the bacterial community, tracked changes that were already happening, or responded to something else that also affected those compounds.
The scale of the catalogue does not make it a guide to what a person should eat. The team identified only four statistically significant links between individual viral groups and diet in this dataset. That number depends on what the study measured and the people it included. It should not be read as proof that diet has no effect or that any food changes gut viruses in a way that improves health.
The advance is a more detailed picture of what lives alongside gut bacteria and how those communities vary. The next step is finding out which links reflect cause and effect. This study did not test a diet, a treatment, or a way to improve health by acting on the catalogue.
Open this article on its own → Explore the related Living Magazine →
Longevity & Healthspan
After a death in a pediatric gene therapy trial, investigators return to the safety evidence
The CAP-002 trial was terminated after its first participant died. A November conference revisited the case. The public record does not establish a reliable way to predict this risk.
The first participant treated in a study of CAP-002, an experimental gene therapy for children with a rare neurologic condition, died in September 2025. The sponsor, Capsida Biotherapeutics, said the autopsy identified cerebral edema, or brain swelling, as the cause of death. The autopsy did not establish what caused the swelling.
The trial was studying children with STXBP1-related encephalopathy, a genetic condition that can affect movement and development and cause seizures. Capsida initially paused the study and later announced in May 2026 that it would close it. The federal trial registry lists one actual participant and says the trial was terminated because a stopping rule was met. It does not contain posted results.
On November 13, the American Society of Gene & Cell Therapy devoted part of its conference safety session to the case. Ingo Helbig of Children’s Hospital of Philadelphia and Nicholas Flytzanis of Capsida presented on the fatal event and its investigation. The public conference program confirms what they addressed; it does not establish a definitive explanation or validate an approach to predict the risk.
The distinction matters for families considering future trials. A single case can reveal a serious hazard that deserves investigation and can be enough to stop a study. It cannot show how often the same harm would occur in others, or tell us whether it applies to other therapies. Nor did this trial establish whether CAP-002 helps children with the condition.
What to watch next is whether investigators publish a fuller account and explain which conclusions the evidence supports, which remain uncertain, and how those findings will be shared with families and independent safety reviewers. The case is a reminder that medical progress depends not only on discovering what might help, but also on taking unexpected harm seriously before moving forward.
Read the clinical trial registry record
Read the sponsor’s May update to families
Read the American Society of Gene & Cell Therapy conference program
Read about STXBP1-related disorders from Children’s Hospital of Philadelphia
Editorial evidence note
An Early Eye Trial Tests the Safety of Partial Reprogramming
Life Biosciences reported preliminary observations in three people with glaucoma. The trial has not shown that the treatment restores vision.
Partial reprogramming aims to change how cells use their genes without turning them into a different kind of cell. The clinical question is whether such a change can help a damaged tissue recover function without causing harm. In a 2020 study, researchers reported improvements in measures of vision in aged mice and in a mouse model of glaucoma. That was a reason to investigate the approach, not evidence that it works in people.
Life Biosciences announced on June 9, 2026, that the first participant had received ER-100 in its phase 1 study. The study includes people with open-angle glaucoma and people with another optic nerve condition caused by interrupted blood flow. Its main purpose is to assess safety and tolerability. On October 8, the company reported no serious adverse events or dose-limiting toxicities through 56 days in the first three glaucoma participants. Two showed improvements on visual-field testing, which measures how well someone sees across different parts of their field of view. With three participants and no control group, the observation does not establish that the treatment caused the changes.
Eight weeks also cannot answer longer-term safety questions. A separate mouse study using a different reprogramming approach found tumors, a reason to monitor that possibility rather than an estimate of ER-100’s cancer risk. The registered eye trial plans follow-up through five years.
The milestone that would change the clinical picture is a controlled study showing that people see better for longer, alongside evidence that the benefits outweigh the risks.
Registered phase 1 trial · June first-participant announcement · October sponsor interim report · Mouse vision study · Separate mouse safety study
Open this article on its own → Explore the related Living Magazine →